US launch of EKTERLY® gaining strong momentum with $13.7 million in net product revenue for the third quarter 937 patient start forms received through October, reflecting...
KONFIDENT-S participants who switched to sebetralstat reported being very or extremely satisfied Interim results from KONFIDENT-KID show sebetralstat enables early, effective,...
KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today announced that the Company will participate in a fireside chat at each of the following upcoming investor conferences: Stifel...
KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) will host a conference call and webcast on Tuesday, November 11, 2025, at 8:30 a.m. ET to review the Company’s third quarter financial results and provide...
KalVista Pharmaceuticals , Inc. (Nasdaq: KALV) today announced the acceptance of one abstract for late-breaking oral presentation and three for poster presentation at the American College of Allergy,...
KalVista Pharmaceuticals , Inc. (Nasdaq: KALV) today announced the acceptance of one abstract for late-breaking oral presentation and three for poster presentation at the American College of Allergy,...
Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. The latest...
Findings from KONFIDENT and KONFIDENT-S show rapid, effective treatment of HAE attacks among European participants; patient survey highlights barriers linked to injectable therapies
KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced the appointments of Bilal Arif as Chief Operating Officer and Linea Aspesi as Chief People Officer, effective October 6, 2025. “I...
Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. KalVista...